NCT06059456 - Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24 | Biotech Hunter

Enrollment

2,078

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2023

Conditions

Influenza Immunization (Healthy Volunteers)

Interventions

BIOLOGICAL

Quadrivalent Influenza Vaccine

Intramuscular or subcutaneous administration

BIOLOGICAL

High-Dose Quadrivalent Influenza Vaccine

Intramuscular or subcutaneous administration

Trial Locations (11)

Investigational Site Number : 2760001, Martinsried

Investigational Site Number : 2760002, Martinsried

Investigational Site Number : 2760003, Martinsried

Investigational Site Number : 2760004, Martinsried

Investigational Site Number : 2760005, Martinsried

Investigational Site Number : 2760006, Martinsried

Investigational Site Number : 2760007, Martinsried

Investigational Site Number : 2760008, Martinsried

Investigational Site Number : 2760009, Martinsried

Investigational Site Number : 2760010, Martinsried

Investigational Site Number : 2460001, Helsinki